July 27, 2018

**Mini-Symposia Announced for San Antonio Breast Cancer Symposium®**

*Man vs. Machine and Over and Under Treatment are on the schedule*

SAN ANTONIO — The San Antonio Breast Cancer Symposium® (SABCS®) has announced two mini-symposia for the 41st annual event, Dec. 4-8, 2018.

Panelists in “Man vs. Machine: Now and in the Future” will discuss the role artificial intelligence and machine learning has in breast cancer treatment. Panelists in “Over and Under Treatment: The Bookends That Keep Us from Getting It Right for Each Patient,” will explore each end of the treatment spectrum.

**Man vs. Machine: Now and in the Future** will be moderated by Jenny C. Chang, MD of Houston Memorial Hospital, Houston.

**Participants:**
- **Alan Karthikesalingam,** MD, PhD of DeepMind, London will speak on artificial intelligence for healthcare.
- **Nico Karssemeijer,** PhD of Radboud University Medical Centre, Nijmegen, Netherlands will discuss deep learning systems for reading mammograms and breast tomosynthesis.
- **Andrew H. Beck,** MD, PhD co-founder of PathAI in Cambridge, Massachusetts will cover artificial intelligence to optimize the accuracy and predictability of breast cancer pathology.

**Over and Under Treatment: The Bookends That Keep Us from Getting It Right for Each Patient** will be moderated by Eric P. Winer, MD of the Dana-Faber Cancer Institute in Boston.

**Participants:**
- **Reshma Jagsi,** MD, DPhil, Director of the Center for Bioethics and Social Sciences in Medicine at the University of Michigan, Ann Arbor, Michigan, will discuss overtreatment.
- **Rachel A. Freedman,** MD of the Dana-Faber Cancer Institute will cover missed opportunities and the perils of undertreatment.

The mini-symposia will be held in Hall 3 of the Henry B. Gonzalez Convention Center. Times will be announced at a later date.

**About SABCS®**
Since 1977 the San Antonio Breast Cancer Symposium® (SABCS®) has been the leading scientific conference for basic scientists, physician-scientists, clinical investigators and breast care providers, and advocates seeking an exchange of new information in experimental biology, etiology, prevention, diagnosis, and therapy of premalignant breast disease and breast cancer. Founded, owned and operated by UT Health San Antonio, the symposium has grown to a five-day event attended by an international audience of academic investigators and private physicians from over 80 countries to attain information through abstract presentations, panel discussions, research findings and
state-of-the-art educational sessions. UT Health San Antonio — Mays Cancer Center, with co-sponsors, Baylor College of Medicine — Dan L Duncan Comprehensive Cancer Center, and the American Association of Cancer Research, support SABCS®, which provides education and accessibility to the latest information regarding the prevention, diagnosis, and treatment of premalignant breast cancer and breast disease.

###